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Background:  Poor adoption of mineralocorticoid receptor antagonist therapy (MRA) is a major gap in evidence-based care in the 
treatment of heart failure (HF). In order to improve care, the medical community needs a better understanding of the barriers experienced 
by providers.
methods:  We conducted focus groups of providers (n=42) from five populations: outpatient primary care, hospital medicine, cardiology, 
and pharmacy staff, and internal medicine residents. Focus groups entailed a mix of open-ended question and answer discussion, 
freewriting and brainstorming exercises, and polling. Focus group transcripts were analyzed with NVivo qualitative analysis software using 
iterative coding techniques that tagged between consideration of past research and emergent data.
results:  Eight categories of barriers, centered at the provider, system, and patient levels, emerged as salient for understanding gaps in 
MRA prescription and monitoring (Table).
Summary of Major Themes Identified by Providers as Limiting MRA Adoption
Additional findings
Provider-centered barriers
Lack of familiarity or experience Knowledge of eplerenone was especially poor among non-cardiology providers
Unclear provider roles and responsibilities Non-cardiologists deferred to cardiology for management.
Poor transitions of care Providers were hesitant to start patients on a new drug requiring additional monitoring.
System-centered barriers
System overload Time constraints, , limited appointment availability
Lack of systematic monitoring protocols No facility-wide standards, no reminders for incomplete labs, inadequate follow-up post-hospitalization
Patient-centered barriers
Perceived non adherence Social and behavioral factors were noted as limitations to therapy
Potential for side effects Possible impact on kidney function, potassium
Polypharmacy, comorbidities Patients on complex medical regimens
conclusion:  Providers experience a diversity of barriers. The study confirmed and strengthened certain barriers noted in past research, 
such as lack of knowledge/experience, concern for side effects and nonadherence. However, we also discovered unexpected barriers 
related to transitions of care, provider role confusion, system overload, and inadequate management tools. Given the multiple levels of 
barriers identified, multimodal intervention strategies may be required to improve MRA adoption in clinical practice.
